Calcium channel blockers not found to increase risk of breast cancer
the ONA take:
According to findings presented at the 2014 American Heart Association Scientific in Chicago, Illinois, researchers from the Intermountain Medical Center Heart Institute in Murray, Utah, have found that women who take calcium channel blockers to treat their hypertension are not at increased risk for developing breast cancer.
Prompted by a study conducted last year at the Fred Hutchinson Cancer Research Center in Seattle, Washington, researchers conducted two studies by analyzing data from the records of more than 3,700 women ages 50 to 70 years with no history of breast cancer who had used calcium channel blockers long-term to treat their high blood pressure.
For each study, researchers compared women who had long-term use of calcium channel blockers to similar women who did not take those medications. In one study, they found a slight increase in breast cancer risk, and a 50% decreased risk in the second study.
The second study's findings were significant, but the odds of breast cancer were much lower than those observed in the study at Fred Hutchinson. As a result, the researchers recommend the continued use of calcium channel blockers to treat hypertension, thereby reducing the risk of myocardial infarction and stroke.
Women who take calcium channel blockers to treat their hypertension are not at increased risk.
Researchers analyzed the records of more than 3,700 women who had no history of breast cancer, and who had long-term use of calcium channel blocker medications to control their blood pressure. Researchers found only a minimal increase in risk in one study and a 50 percent reduced risk in a second, leading them to recommend the continued use of these important medications to help prevent heart attack and stroke.
Findings from the Intermountain Medical Center Heart Institute study will be presented at the 2014 American Heart Association Scientific in Chicago at 10:30, EST, on Wednesday, November 19.
Sign Up for Free e-newsletters
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
- Urine Drug Testing Policy Can Assist Opioid Treatment Decisions
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|